In the research drug competition is fierce, the government and enterprises cooperate to eat delicious ... The focus of global antiviral drug research and development is here.

Drug companies, governments and academic institutions are also working to develop new drugs and vaccines in response to the global outbreak of COVID-19 new crown pneumonia this year.
outbreak of new crown pneumonia in the world, so that antiviral drugs back into the public view, new drugs and vaccinedevelopment is touching the hearts of all.
01 Global Anti-Infective Drugs: Market feedback is weak or will rebound from the global market for drugs, 2010-2019 the global basically maintained the annual 50-60 new drug market rate of stable, but anti-infective drugs on the market is large fluctuations.
statistics show that the output of such drugs in 2012 is almost 0, in recent years, with the support of the government and international organizations, the relevant regulatory regulations, the development of anti-infective drugs gradually ushered in a small climax, the number of new drugs on the market increased year by year.
but this number is in 2019 and is falling again, mainly because of weak feedback from the market.
the development of antimicrobial drugs is more "deplorable" than antiviral drugs.
data show that between December 2018 and February 2020, the Index of Anti-Infective Drugs Research and Development showed a very clear downward trend for the whole of 2019 compared with the NASDAQ and Dow Indices.
for a long time, the research and development of new antibiotics has not been enough.
's cautious use of antibiotics has prevented new antibiotic research and development companies from getting the market returns they deserve, and the market value of anti-infective drug companies has fallen sharply.
In 2019, three antibiotic companies filed for bankruptcy, including Achaogen, Melinata Therapeutics and Motif Bio.
, Achaogen filed for bankruptcy just nine months after its drug Plazomicin went on sale.
, industry sources said, this year's outbreak will promote anti-infective drug research and development ushered in a clear rebound.
02 Antiviral Drugs: The market is growing slowly In the fierce competition for research drugs with HIV can be effectively controlled, HCV can be gradually cured, antiviral drugs in the past few years the development of investment is relatively reduced.
the global antiviral drug market grew at a CAGR of 8.2% in 2015-2019 and the global antiviral drug market was about $56 billion in 2019, but this figure is somewhat "not worth mentioning" compared with the large size of the oncology drug market.
market expects the compound growth rate of the antiviral drug market to be only 2.3% in 2020-2027, although the increase in the prevalence of viral infections will drive up demand for antiviral drugs, but fierce competition and price reductionwillwill will lead to small overall growth in the market.
there are currently about 620 approved and marketed antiviral drugs and vaccines worldwide.
of the world's 10 best-selling antiviral drugs, eight are used to treat HIV and two are for HCV.
six of the 10 drugs came from Gilead.
classified from the technical type, small molecule drugs accounted for 23%, biologics accounted for 77%.
figures also reflect that the vast majority of biologics are vaccine-based products, and whether antiviral drugs or small molecule types dominate.
market information shows that the global research of the product pipeline, the proportion of antiviral drugs in the research of more than 2,600 antiviral drugs and vaccines, including 59 in the registration phase, clinical Phase III 192.
this also bodes well for the next three years or so, more than 200 antiviral drugs or vaccines could be available in different countries and regions around the world.
but unavoidable problem is that there are relatively few innovative and new technologies in the research of antiviral drug targets.
in the study of drug indications TOP20 statistics can be seen, the COVID-19 research and development of a total of 613, which is inseparable from the rapid spread of the new crown virus in the world, the outbreak prompted the global in a very short period of time to biomedical research and development of technical forces assembled for anti-viral new drugs research and development.
followed by HIV, followed by influenza, hepatitis B, hepatitis C and so on.
in the research drugs, the proportion of small molecule drugs is relatively small, on the one hand, because the vaccine occupies a large proportion, on the other hand, also reflects that biotechnology in recent years has been very significant progress.
from the role mechanism of drugs, to COVID-19 as an example, the most popular research targets have 87 related projects, which reflects the current research and development of antiviral drugs there are different enterprises "following the wind", target homogenization of serious situation.
today's biotechnology, China and the United States are leading the major development boom.
antivirals in the research drug / vaccine TOP20 countries and regions of the relevant statistics show that there are currently 1,300 research projects in the United States, China has 499 projects.
from the classification of antiviral drugs in the study countries, different disease-prone countries have a certain impact on the distribution of research and development projects.
COVID-19 in the United States 99 research projects, 23 in China, HIV, influenza research and development projects are also the United States leader, HBV is China's largest number of research projects.
03 Anti-Coronavirus Drug Research and Development: The government and enterprises need to complete patent data shows that the patent application signed for anti-coronavirus drugs and vaccines in 2003-2004 ushered in a very obvious outbreak, but with the stability of the SARS epidemic, the next few small, faster-controlled outbreaks for the patent application of this type of drugs did not play a significant role, which also led to the coronavirus drugs and vaccine patent invention technology technology is far below the benchmark.
from the perspective of patent applications, nearly half of the world's invention patents come from the United States, which also in the United States developed pharmaceutical technology status and many pharmaceutical companies.
and China accounts for one-sixth of the world's invention patents, at 17%.
other countries' investment in anti-coronavirus drugs is relatively weak.
but cannot deny that although the number of patents in the United States is the largest, but in recent years the growth rate of U.S. patents in a downward trend, while China in the number of second place, but the trend of growth is more obvious, the growth rate of the world's first, far behind other countries.
this also shows that China's anti-coronavirus drug research and development of the degree of increasing attention.
from the physical perspective of patent applications, 48 per cent of applications in the field of anti-coronavirus came from businesses and 25 per cent from government and academic institutions ( A and G), a figure higher than the global benchmark, reflecting the fact that governments and academic institutions are important research and development forces in the field of anti-coronavirus technology.
in the anti-coronavirus drug research and development, need to be jointly completed by the government and enterprises.
for the new crown virus, there are currently 175 vaccines in the research world, in the research phase in clinical phase III has three products, one from China, the State Drug Administration set up to speed up the regulatory approach for the development of new crown vaccine also provides favorable support.
at the same time, market information shows that the number of clinical trials and the development of global outbreaks show a high degree of correlation.
In early March this year, 162 clinical institutions in China carried out the corresponding clinical development of the new crown, on March 16 to 254, the United States only 9, March 30, China launched a new crown clinical trial institutions reached 459, this number to July 8 to 510;
in the whole treatment process of new coronary pneumonia, antiviral treatment is only one aspect of treatment, experts believe that the rehabilitation of patients with new coronary pneumonia also need comprehensive assessment, patients with lung injury, such as the treatment of pulmonary fibrosis, may also become a new clinical needs for clinical trials, new drug development provides a new direction.
.